Osteoporosis and Your Teeth: Separating Myths from Evidence

Tooth enamel and dentin are not the same tissue as the cortical and trabecular bone affected by osteoporosis. Teeth do not lose mineral content as a result of systemic osteoporosis the way vertebrae, hips, and wrists do. Dental decay is caused by acid-producing bacteria dissolving enamel from the outside in, not by reduced bone mineral density.

However, osteoporosis does affect the jawbone, and that matters. The alveolar bone that surrounds tooth roots and supports implants is composed of the same trabecular and cortical bone that osteoporosis affects elsewhere in the skeleton. Studies have found that lower jaw bone mineral density is associated with greater alveolar bone loss in patients with periodontal disease, though causality is complex and confounded by shared risk factors including age and estrogen status.

The practical implication is that osteoporosis does not cause cavities and does not inherently weaken the structure of teeth themselves. Its dental relevance is primarily through effects on supporting bone and through the medications used to treat it.

Medication-related osteonecrosis of the jaw (MRONJ) is the most clinically significant dental concern for patients with osteoporosis. It refers to the development of exposed, non-healing bone in the jaw following dental procedures or, less commonly, spontaneously. The condition is associated with several medications that suppress bone resorption, most notably bisphosphonates.

Bisphosphonates used for osteoporosis include oral agents such as alendronate (Fosamax), risedronate (Actonel), and ibandronate (Boniva), and intravenous agents such as zoledronic acid (Reclast) given annually. These medications incorporate into bone and have very long half-lives. IV bisphosphonates at the doses used for cancer-related bone disease carry a much higher MRONJ risk than oral bisphosphonates at the doses used for osteoporosis.

For patients taking oral bisphosphonates for osteoporosis at standard doses, the absolute risk of MRONJ following routine dental procedures is low, estimated at roughly 0.01 to 0.1%. The risk increases with treatment duration beyond four years, with concurrent corticosteroid use, and with more invasive procedures such as extractions and implant placement. This risk is real but small, and should not lead to blanket avoidance of necessary dental treatment.

Denosumab (Prolia), a RANK-L inhibitor used for osteoporosis, carries a similar or slightly higher MRONJ risk compared to oral bisphosphonates. Its mechanism of action is different from bisphosphonates, but the clinical result is the same suppression of osteoclast activity that appears to underlie the MRONJ risk. Notably, denosumab does not incorporate into bone the way bisphosphonates do, so its effect is reversible after discontinuation.

Anti-angiogenic medications such as bevacizumab (Avastin) and sunitinib, used primarily in cancer treatment rather than osteoporosis, also carry MRONJ risk, though through a different mechanism related to impaired blood vessel formation rather than osteoclast suppression. These are much less commonly encountered in dental contexts than bisphosphonates.

The key point is that the dental team needs to know every medication you take, not just the ones you think are dental-relevant. Bisphosphonate exposure several years ago is still relevant because of the drug's long bone half-life. A thorough medication history at every dental visit is not a formality.

Osteoporosis is not an absolute contraindication to dental implants. Studies examining implant outcomes in patients with osteoporosis have generally found success rates broadly comparable to those in patients without osteoporosis, with some studies showing modestly lower success in the most severely affected patients.

The more clinically significant question is whether the patient is taking antiresorptive medication such as a bisphosphonate or denosumab. For patients on these medications, the MRONJ risk associated with implant surgery (which involves bone trauma and healing) requires careful risk-benefit analysis and, in most cases, coordination with the prescribing physician about whether a medication holiday before surgery is appropriate or advisable.

A drug holiday (temporarily stopping bisphosphonate therapy before implant surgery) remains controversial in the literature. Because bisphosphonates are incorporated into bone, stopping oral dosing does not immediately clear the drug from the jaw. Some guidelines suggest stopping for three months before and three months after major oral surgery, while others find no clear benefit for patients on shorter treatment duration. This decision is made collaboratively with the prescribing physician.

Jaw bone density is categorized clinically by the Lekholm and Zarb system (Types I through IV). Type I bone is dense cortical bone with little trabecular space, found in the front of the lower jaw in many patients. Type IV bone is minimal cortical shell with very sparse trabecular bone, more commonly found in the posterior upper jaw.

Implants placed in lower-density bone (Types III and IV) have a higher failure rate than those in denser bone, not because of systemic osteoporosis specifically but because the bone-implant contact surface is smaller and the primary stability achieved at placement is lower. Techniques to compensate include using wider or longer implants where anatomy permits, using surface-treated implants that promote osseointegration, and extending the healing time before loading.

For patients with systemic osteoporosis, the jaw bone density may be lower than in age-matched patients without osteoporosis, though the jaw is often less severely affected than the spine and hip. A CBCT scan before implant planning provides three-dimensional bone density and volume information specific to the actual implant site, which is more clinically useful than a general DXA scan result.

The single most important step is complete medication disclosure at every dental visit, including the drug name, dose, route (oral vs IV), duration of use, and whether you have had any recent dental complications. This allows your dentist to stratify your MRONJ risk accurately and coordinate with your prescribing physician before any invasive procedure.

Routine preventive care, cleanings, non-surgical periodontal treatment, and restorative work that does not involve bone manipulation carries negligible MRONJ risk and should not be avoided or deferred because of osteoporosis medications. The risk is concentrated in procedures that involve bone surgery: extractions, implant placement, and periodontal surgery.

Maintaining excellent oral hygiene is particularly important for patients on antiresorptive medications, because periodontal disease and the extractions it may eventually require represent the most common pathway to MRONJ in this population. Preserving teeth through good home care and regular professional visits reduces the need for future bone-touching procedures.